Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
722 Evaluation of the effects of pembrolizumab alone and in combination(s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional spatial profiling (CIVO®)
Compose a Response to This Article
Other responses
No responses have been published for this article.
